Posted by Michael Wonder on 08 Nov 2023
PHARMAC publishes agenda for November 2023 PTAC meeting
8 November 2023 - Another underwhelming agenda; yet again there is no application for a cancer medicine.
The agenda for this week's PTAC meeting has been published; the Committee will consider applications for the following medicines:
- Secukinumab - ankylosing spondylitis
- Memantine hydrochloride - dementia (first-line)
- Memantine hydrochloride - dementia (second-line)
- Belimumab - lupus nephritis
- Upadacitinib monohydrate - Crohn's disease
- Budesonide with eformoterol fumarate dihydrate and glycopyrronium bromide - chronic obstructive pulmonary disease
- Cladribine - multiple sclerosis
- Guselkumab - psoriatic arthritis
